Gene therapy injection takes aim at Hard-to-Treat blood cancers
NCT ID NCT06533579
First seen Jun 26, 2026 · Last updated Aug 07, 2026 · Updated 3 times
Summary
This early-stage trial tests a single-dose gene therapy called VNX-101 for people with certain blood cancers (like leukemia or lymphoma) that have returned or not responded to standard treatment. The therapy delivers instructions to the body to make a protein that helps immune cells find and attack cancer cells. About 32 adults and teens will receive one of four dose levels to check safety and how well it works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- VNX-101 (a gene therapy that delivers instructions to make a protein that helps immune cells attack cancer cells)
- What this could lead to
- If successful, this could offer a new treatment option for people with certain blood cancers that have not responded to other therapies.
- What could go wrong
- This is an early, first-in-human trial with only 32 participants. The gene therapy may not work or could cause serious side effects. It is not a cure and long-term safety is unknown.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
City of Hope
RECRUITINGDuarte, California, 91010, United States
-
Colorado Blood Cancer Institute
RECRUITINGDenver, Colorado, 80218, United States
-
Mayo Clinic, Clinical Trials Referral Office
RECRUITINGJacksonville, Florida, 32224, United States
-
Mayo Clinic, Clinical Trials Referral Office
RECRUITINGRochester, Minnesota, 55905, United States
-
New York Medical College
RECRUITINGValhalla, New York, 10595, United States
-
Oregon Health & Science University
RECRUITINGPortland, Oregon, 97239, United States
-
The Ohio State University Wexner Medical Center
RECRUITINGColumbus, Ohio, 43210, United States
-
TriStar BMT
RECRUITINGNashville, Tennessee, 37203, United States
-
University of North Carolina at Chapel Hill/ University of North Carolina Medical Center
RECRUITINGChapel Hill, North Carolina, 27599, United States
-
University of Texas MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
-
Valkyrie Clinical Trials
RECRUITINGLos Angeles, California, 90067, United States
Contact Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can immune cells plus a checkpoint drug outsmart lymphoma?
- Can an immune booster outsmart brain lymphoma?
- A shot at safer CAR t: early brain protection for lymphoma patients?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a Triple-Drug combo wipe out Slow-Growing lymphomas?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?